These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1964202)

  • 1. Rolipram, a phosphodiesterase inhibitor, in the treatment of two male patients with congenital nephrogenic diabetes insipidus.
    Bichet DG; Ruel N; Arthus MF; Lonergan M
    Nephron; 1990; 56(4):449-50. PubMed ID: 1964202
    [No Abstract]   [Full Text] [Related]  

  • 2. Causes of the urinary concentrating defect in mice with nephrogenic diabetes insipidus.
    Valtin H; Coffey AK; O'Sullivan DJ; Homma S; Dousa TP
    Physiol Bohemoslov; 1990; 39(1):103-11. PubMed ID: 2165265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of intramembranous particle clusters in mice with nephrogenic diabetes insipidus.
    Coffey AK; O'Sullivan DJ; Homma S; Dousa TP; Valtin H
    Am J Physiol; 1991 Oct; 261(4 Pt 2):F640-6. PubMed ID: 1656782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pathogenesis and treatment of congenital nephrogenic diabetes insipidus (author's transl)(proceedings)].
    Dubost M; Berthezène F; Pousset G; Orgiazzi J; Accominotti JC
    Ann Endocrinol (Paris); 1976; 37(4):313-4. PubMed ID: 192128
    [No Abstract]   [Full Text] [Related]  

  • 5. Protection by a cyclic AMP-specific phosphodiesterase inhibitor, rolipram, and dibutyryl cyclic AMP against Propionibacterium acnes and lipopolysaccharide-induced mouse hepatitis.
    Taguchi I; Oka K; Kitamura K; Sugiura M; Oku A; Matsumoto M
    Inflamm Res; 1999 Jul; 48(7):380-5. PubMed ID: 10450787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and biochemical effects of the selective phosphodiesterase inhibitor rolipram in depressed inpatients controlled by determination of plasma level.
    Laux G; Becker T; Kühne G; Lesch KP; Riederer P; Beckmann H
    Pharmacopsychiatry; 1988 Nov; 21(6):378-9. PubMed ID: 3244773
    [No Abstract]   [Full Text] [Related]  

  • 7. Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4.
    Miotla JM; Teixeira MM; Hellewell PG
    Am J Respir Cell Mol Biol; 1998 Mar; 18(3):411-20. PubMed ID: 9490659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of cyclic AMP systems in morphine physical dependence in mice: prevention of development of morphine dependence by rolipram, a phosphodiesterase 4 inhibitor.
    Mamiya T; Noda Y; Ren X; Hamdy M; Furukawa S; Kameyama T; Yamada K; Nabeshima T
    Br J Pharmacol; 2001 Mar; 132(5):1111-7. PubMed ID: 11226142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of cAMP-phosphodiesterase isozymes in pathogenesis of murine nephrogenic diabetes insipidus.
    Homma S; Gapstur SM; Coffey A; Valtin H; Dousa TP
    Am J Physiol; 1991 Aug; 261(2 Pt 2):F345-53. PubMed ID: 1652209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol.
    Dent G; Giembycz MA; Evans PM; Rabe KF; Barnes PJ
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1167-74. PubMed ID: 7996422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung.
    Gonçalves de Moraes VL; Singer M; Vargaftig BB; Chignard M
    Br J Pharmacol; 1998 Feb; 123(4):631-6. PubMed ID: 9517381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
    Willette RN; Shiloh AO; Sauermelch CF; Sulpizio A; Michell MP; Cieslinski LB; Torphy TJ; Ohlstein EH
    J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock.
    Badger AM; Olivera DL; Esser KM
    Circ Shock; 1994 Dec; 44(4):188-95. PubMed ID: 7628060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram.
    Underwood DC; Osborn RR; Novak LB; Matthews JK; Newsholme SJ; Undem BJ; Hand JM; Torphy TJ
    J Pharmacol Exp Ther; 1993 Jul; 266(1):306-13. PubMed ID: 8392555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of a selective cAMP phosphodiesterase inhibitor, rolipram, on methamphetamine-induced behavior.
    Iyo M; Maeda Y; Inada T; Kitao Y; Sasaki H; Fukui S
    Neuropsychopharmacology; 1995 Aug; 13(1):33-9. PubMed ID: 8526969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preliminary results of a double-blind study between rolipram and desipramine in hospitalized patients with major depressive symptoms].
    Guiot-Goffioul F; Gerard-Vandenhove MA; Troisfontaines B; Breulet M; von Frenckell R; Bobon D
    Acta Psychiatr Belg; 1987; 87(2):230-5. PubMed ID: 3618273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism-induced defects in memory function and cerebral cyclic AMP signal transduction system in rats.
    Nagakura A; Niimura M; Takeo S
    Br J Pharmacol; 2002 Apr; 135(7):1783-93. PubMed ID: 11934820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic intervention in a rat model of ARDS: IV. Phosphodiesterase IV inhibition.
    Turner CR; Esser KM; Wheeldon EB
    Circ Shock; 1993 Mar; 39(3):237-45. PubMed ID: 8384094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High activity of low-Michaelis-Menten constant 3', 5'-cyclic adenosine monophosphate-phosphodiesterase isozymes in renal inner medulla of mice with hereditary nephrogenic diabetes insipidus.
    Takeda S; Lin CT; Morgano PG; McIntyre SJ; Dousa TP
    Endocrinology; 1991 Jul; 129(1):287-94. PubMed ID: 1647298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase 4 inhibitors, rolipram and diazepam block the adaptive changes observed during morphine withdrawal in the heart.
    González-Cuello A; Sánchez L; Hernández J; Teresa Castells M; Victoria Milanés M; Laorden ML
    Eur J Pharmacol; 2007 Sep; 570(1-3):1-9. PubMed ID: 17601555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.